These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 21166160

  • 1. [Pioglitazone inhibits cardiac hypertrophy of rats in vitro and in vivo].
    Ye P, Zhang C, Wu SM, Liu YX.
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2005 Feb; 21(1):35-9. PubMed ID: 21166160
    [Abstract] [Full Text] [Related]

  • 2. Effect of pioglitazone on the expression of inflammatory cytokines in attenuating rat cardiomyocyte hypertrophy.
    Ye P, Yang W, Wu SM, Sheng L.
    Methods Find Exp Clin Pharmacol; 2006 Dec; 28(10):691-6. PubMed ID: 17235413
    [Abstract] [Full Text] [Related]

  • 3. Atorvastatin attenuating down-regulation of peroxisome proliferator-activated receptor gamma in preventing cardiac hypertrophy of rats in vitro and in vivo.
    Ye P, Sheng L, Zhang C, Liu Y.
    J Pharm Pharm Sci; 2006 Dec; 9(3):365-75. PubMed ID: 17207419
    [Abstract] [Full Text] [Related]

  • 4. Overexpression of miR-142-3p improves mitochondrial function in cardiac hypertrophy.
    Liu BL, Cheng M, Hu S, Wang S, Wang L, Tu X, Huang CX, Jiang H, Wu G.
    Biomed Pharmacother; 2018 Dec; 108():1347-1356. PubMed ID: 30372837
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Astragaloside IV protects against isoproterenol-induced cardiac hypertrophy by regulating NF-κB/PGC-1α signaling mediated energy biosynthesis.
    Zhang S, Tang F, Yang Y, Lu M, Luan A, Zhang J, Yang J, Wang H.
    PLoS One; 2015 Dec; 10(3):e0118759. PubMed ID: 25738576
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats.
    Sakai S, Miyauchi T, Irukayama-Tomobe Y, Ogata T, Goto K, Yamaguchi I.
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():16S-20S. PubMed ID: 12193046
    [Abstract] [Full Text] [Related]

  • 9. Cardiomyocyte-specific transgenic expression of lysyl oxidase-like protein-1 induces cardiac hypertrophy in mice.
    Ohmura H, Yasukawa H, Minami T, Sugi Y, Oba T, Nagata T, Kyogoku S, Ohshima H, Aoki H, Imaizumi T.
    Hypertens Res; 2012 Nov; 35(11):1063-8. PubMed ID: 22763477
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Let-7a Is an Antihypertrophic Regulator in the Heart via Targeting Calmodulin.
    Zhou X, Sun F, Luo S, Zhao W, Yang T, Zhang G, Gao M, Lu R, Shu Y, Mu W, Zhuang Y, Ding F, Xu C, Lu Y.
    Int J Biol Sci; 2017 Nov; 13(1):22-31. PubMed ID: 28123343
    [Abstract] [Full Text] [Related]

  • 12. B-type natriuretic peptide attenuates cardiac hypertrophy via the transforming growth factor-ß1/smad7 pathway in vivo and in vitro.
    He JG, Chen YL, Chen BL, Huang YY, Yao FJ, Chen SL, Dong YG.
    Clin Exp Pharmacol Physiol; 2010 Mar; 37(3):283-9. PubMed ID: 19719752
    [Abstract] [Full Text] [Related]

  • 13. In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy.
    He T, Chen L, Chen Y, Han Y, Yang WQ, Jin MW.
    Cardiovasc Drugs Ther; 2012 Apr; 26(2):109-20. PubMed ID: 22183794
    [Abstract] [Full Text] [Related]

  • 14. [Atorvastatin upregulates the expression of PPAR alpha/gamma and inhibits the hypertrophy of cardiac myocytes in vitro].
    Sheng L, Ye P, Liu YX.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Dec; 33(12):1080-4. PubMed ID: 16563274
    [Abstract] [Full Text] [Related]

  • 15. Overexpression of cdk Inhibitor p16INK4a by adenovirus vector inhibits cardiac hypertrophy in vitro and in vivo: a novel strategy for the gene therapy of cardiac hypertrophy.
    Nozato T, Ito H, Watanabe M, Ono Y, Adachi S, Tanaka H, Hiroe M, Sunamori M, Marum F.
    J Mol Cell Cardiol; 2001 Aug; 33(8):1493-504. PubMed ID: 11448137
    [Abstract] [Full Text] [Related]

  • 16. Effect of endostatin overexpression on angiotensin II-induced cardiac hypertrophy in rats.
    Dai YJ, Gong JX, Bian R.
    Chin Med J (Engl); 2019 Nov 20; 132(22):2716-2723. PubMed ID: 31725448
    [Abstract] [Full Text] [Related]

  • 17. Activation of PPARgamma by pioglitazone does not attenuate left ventricular hypertrophy following aortic banding in rats.
    Weiss CS, Hagenmüller M, Pichler M, Münz S, Ochs M, Buss SJ, Bekeredjian R, Katus HA, Hardt SE.
    Naunyn Schmiedebergs Arch Pharmacol; 2010 Apr 20; 381(4):285-95. PubMed ID: 20107770
    [Abstract] [Full Text] [Related]

  • 18. Cellular physiology of rat cardiac myocytes in cardiac fibrosis: in vitro simulation using the cardiac myocyte/cardiac non-myocyte co-culture system.
    Ikeda K, Tojo K, Udagawa T, Otsubo C, Ishikawa M, Tokudome G, Hosoya T, Tajima N, Nakao K, Kawamura M.
    Hypertens Res; 2008 Apr 20; 31(4):693-706. PubMed ID: 18633182
    [Abstract] [Full Text] [Related]

  • 19. Cardiac-specific overexpression of caveolin-3 attenuates cardiac hypertrophy and increases natriuretic peptide expression and signaling.
    Horikawa YT, Panneerselvam M, Kawaraguchi Y, Tsutsumi YM, Ali SS, Balijepalli RC, Murray F, Head BP, Niesman IR, Rieg T, Vallon V, Insel PA, Patel HH, Roth DM.
    J Am Coll Cardiol; 2011 May 31; 57(22):2273-83. PubMed ID: 21616289
    [Abstract] [Full Text] [Related]

  • 20. COX-2 is involved in ET-1-induced hypertrophy of neonatal rat cardiomyocytes: role of NFATc3.
    Li H, Gao S, Ye J, Feng X, Cai Y, Liu Z, Lu J, Li Q, Huang X, Chen S, Liu P.
    Mol Cell Endocrinol; 2014 Feb 15; 382(2):998-1006. PubMed ID: 24291639
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.